David J. Cangemi, M.D.

The overarching aim of this study is to collect data for patients treated with glutamine and describe safety and treatment results. It will also investigate the effectiveness of glutamine for the treatment of Functional Dyspepsia (FD), and to assess the effect of glutamine on intestinal permeability in a larger study in the future. The global hypothesis is that glutamine treatment will be safe to use with good treatment outcomes.

The purpose of this study is to investigate, using several novel techniques, potential pathophysiologic abnormalities that could lead to the development of symptoms of functional dyspepsia.

The overall aim of this study is to investigate the effectiveness of virtual reality (VR) for the treatment of functional dyspepsia (FD).  We hypothesize that patients with FD who use regular sessions of VR will experience a greater improvement in dyspeptic symptoms, as measured by a reduction in symptom scores using the Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM), a visual analog scale for nausea (VAS), a numerical rating scale for abdominal pain (NRS), and the Mayo Bloating Questionnaire, compared to patients with FD who use “sham” VR. 

The purpose of this study is to investigate, using several novel techniques, potential pathophysiologic abnormalities that could lead to the development of symptoms of gastroparesis (GP).  The global hypothesis is that patients with GP will be more likely than controls to have abnormalities in duodenal intestinal permeability.

The purpose of this study is to develop a de novo CIPO-specific PRO that is able to capture change in core CIPO visible signs and symptoms across all etiologies and severity levels, and is fit-for-purpose for use as a primary endpoint in a clinical trial setting

The purpose of this study is to investigate the effectiveness of virtual reality (VR) for the treatment of functional dyspepsia (FD).